Literature DB >> 9457190

Alendronate-induced esophagitis: case report of a recently recognized form of severe esophagitis with esophageal stricture--radiographic features.

J M Ryan1, P Kelsey, B M Ryan, P R Mueller.   

Abstract

Alendronate sodium, an aminobiphosphonate used primarily to treat osteoporosis in postmenopausal women, is known to cause esophagitis. A 71-year-old woman experienced severe, acute esophagitis and severe stricture of the esophagus due to oral alendronate therapy. Unlike in previous cases, she had taken alendronate for 10 months before the onset of complications and the stricture proved resistant to dilation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9457190     DOI: 10.1148/radiology.206.2.9457190

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  8 in total

Review 1.  Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations.

Authors:  Ronald Emkey
Journal:  MedGenMed       Date:  2004-07-19

Review 2.  Alendronate: an update of its use in osteoporosis.

Authors:  M Sharpe; S Noble; C M Spencer
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Esophageal stricture associated with alendronate use.

Authors:  Asit K Paul; Mysore Seetharaman
Journal:  CMAJ       Date:  2011-02-22       Impact factor: 8.262

4.  Exposure to oral bisphosphonates and risk of gastrointestinal cancer.

Authors:  D Choi; S Choi; J Chang; S M Park
Journal:  Osteoporos Int       Date:  2020-02-07       Impact factor: 4.507

Review 5.  Safety of long-term bisphosphonate therapy for the management of osteoporosis.

Authors:  E Michael Lewiecki
Journal:  Drugs       Date:  2011-04-16       Impact factor: 9.546

6.  Exposure to oral bisphosphonates and risk of esophageal cancer.

Authors:  Chris R Cardwell; Christian C Abnet; Marie M Cantwell; Liam J Murray
Journal:  JAMA       Date:  2010-08-11       Impact factor: 56.272

Review 7.  What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates.

Authors:  David Y Graham
Journal:  Dig Dis Sci       Date:  2002-08       Impact factor: 3.199

8.  A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study.

Authors:  Wen-Yuan Lee; Li-Min Sun; Ming-Chia Lin; Ji-An Liang; Shih-Ni Chang; Fung-Chang Sung; Chih-Hsin Muo; Chia-Hung Kao
Journal:  PLoS One       Date:  2012-12-31       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.